J
Juliana Hamzah
Researcher at Harry Perkins Institute of Medical Research
Publications - 34
Citations - 1835
Juliana Hamzah is an academic researcher from Harry Perkins Institute of Medical Research. The author has contributed to research in topics: Angiogenesis & Immunotherapy. The author has an hindex of 20, co-authored 32 publications receiving 1602 citations. Previous affiliations of Juliana Hamzah include University of Western Australia & Sanford-Burnham Institute for Medical Research.
Papers
More filters
Journal ArticleDOI
Vascular normalization in Rgs5-deficient tumours promotes immune destruction
Juliana Hamzah,Manfred Jugold,Fabian Kiessling,Paul Rigby,Mitali Manzur,Hugo H. Marti,Tamer Rabie,Sylvia Kaden,Hermann Josef Gröne,Günter J. Hämmerling,Bernd Arnold,Ruth Ganss +11 more
TL;DR: This is the first demonstration, to the authors' knowledge, of reduced tumour angiogenesis and improved immune therapeutic outcome on loss of a vascular gene function and establishes a previously unrecognized role of G-protein signalling in tumourAngiogenesis.
Journal ArticleDOI
Transtumoral targeting enabled by a novel neuropilin-binding peptide.
Lise Roth,Lilach Agemy,Venkata Ramana Kotamraju,Gary B. Braun,Tambet Teesalu,Kazuki N. Sugahara,Juliana Hamzah,Erkki Ruoslahti +7 more
TL;DR: The truncated form of LyP-1, in which the CendR motif is exposed, is shown to be a promising tool for targeted delivery of therapeutic and diagnostic agents to breast cancers and perhaps other types of tumors.
Journal ArticleDOI
Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy.
TL;DR: Low-dose TNFα promotes both vessel remodeling and antitumor immune responses and acts as a potent adjuvant for active immunotherapy.
Journal ArticleDOI
Specific penetration and accumulation of a homing peptide within atherosclerotic plaques of apolipoprotein E-deficient mice
Juliana Hamzah,Venkata Ramana Kotamraju,Jai Woong Seo,Lilach Agemy,Valentina Fogal,Valentina Fogal,Lisa M. Mahakian,David Peters,Lise Roth,M. Karen J. Gagnon,Katherine W. Ferrara,Erkki Ruoslahti,Erkki Ruoslahti +12 more
TL;DR: Results indicate that LyP-1 is a promising agent for the targeting of atherosclerotic lesions and describes such a delivery system based on a 9-amino acid cyclic peptide, Lyp-1.
Journal ArticleDOI
64Cu-Labeled LyP-1-Dendrimer for PET-CT Imaging of Atherosclerotic Plaque
Jai Woong Seo,Hyounggee Baek,Lisa M. Mahakian,Jiro Kusunose,Juliana Hamzah,Erkki Ruoslahti,Katherine W. Ferrara +6 more
TL;DR: The results suggest that the (LyP- 1)4-dendrimer can be applied for in vivo PET imaging of plaque and that LyP-1 could be further exploited for the delivery of therapeutics with multivalent carriers or nanoparticles.